BR0115527A - Análogos de ácido graxo para o tratamento de distúrbios imflamatórios e autoimunes - Google Patents

Análogos de ácido graxo para o tratamento de distúrbios imflamatórios e autoimunes

Info

Publication number
BR0115527A
BR0115527A BR0115527-0A BR0115527A BR0115527A BR 0115527 A BR0115527 A BR 0115527A BR 0115527 A BR0115527 A BR 0115527A BR 0115527 A BR0115527 A BR 0115527A
Authority
BR
Brazil
Prior art keywords
fatty acid
acid analogues
inflammatory
treatment
autoimmune disorders
Prior art date
Application number
BR0115527-0A
Other languages
English (en)
Inventor
Berge
Rolf
Aukrust
Pal
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Publication of BR0115527A publication Critical patent/BR0115527A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)

Abstract

"ANáLOGOS DE áCIDO GRAXO PARA O TRATAMENTO DE DISTúRBIOS INFLAMATóRIOS E AUTOIMUNES". A presente invenção se refere a análogos de ácido graxo de fórmula geral (I): R~ 1~-[x~ i~ - CH~ 2~]n - COOR~ 2~ (I) : onde R~ 1~ representa: - um C~ 1~-C~ 24~-alceno com uma ou mais duplas ligações e/ou com uma ou mais tríplices ligações; ou - um C~ 1~-C~ 24~-alcino; ou - um C~ 1~-C~ 24~-alquila ou um C~ 1~-C~ 24~-alquila substituído em uma ou diversas posições por um ou mais compostos selecionados do grupo que compreende fluoreto, cloreto, hidróxi, C~ 1~-C~ 4~-alcóxi, C~ 1~-C~ 4~-alquiltio, C~ 2~-C~ 5~-acilóxi ou C~ 1~-C~ 4~-alquila; e - onde R~ 2~ representa hidrogênio ou C~ 1~-C~ 4~-alquila; e - onde n é um inteiro de 1 a 12; e - onde i é um numero ímpar e indica a posição em relação a COOR~ 2~; e - onde Xi independentemente entre si, é selecionado do grupo que consiste de 0, S, SO, SO~ 2~, Se e CH~ 2~; e - com a condição de que pelo menos um de Xi não seja CH~ 2~; que pode ser usado no tratamento e/ou prevenção de distúrbios inflamatórios. Além disso, a invenção se refere a métodos para aumentar a produção endógena de interleucina-10 (IL-10) e suprimir a produção de interleucina-2 (IL-2) em células ou tecidos de mamíferos. A invenção também se refere à inibição da proliferação de células mononucleares periféricas estimuladas.
BR0115527-0A 2000-11-28 2001-11-27 Análogos de ácido graxo para o tratamento de distúrbios imflamatórios e autoimunes BR0115527A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20006008A NO20006008L (no) 2000-11-28 2000-11-28 Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
PCT/NO2001/000470 WO2002043728A1 (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders

Publications (1)

Publication Number Publication Date
BR0115527A true BR0115527A (pt) 2003-09-23

Family

ID=19911849

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115527-0A BR0115527A (pt) 2000-11-28 2001-11-27 Análogos de ácido graxo para o tratamento de distúrbios imflamatórios e autoimunes

Country Status (17)

Country Link
US (2) US8088825B2 (pt)
EP (1) EP1351672B1 (pt)
JP (1) JP4368579B2 (pt)
KR (1) KR100905335B1 (pt)
CN (1) CN1296039C (pt)
AT (1) ATE432071T1 (pt)
AU (2) AU2002223162B2 (pt)
BR (1) BR0115527A (pt)
CA (1) CA2457925C (pt)
DE (1) DE60138834D1 (pt)
ES (1) ES2326159T3 (pt)
MX (1) MXPA03004427A (pt)
NO (1) NO20006008L (pt)
NZ (1) NZ525889A (pt)
RU (1) RU2259823C2 (pt)
WO (1) WO2002043728A1 (pt)
ZA (1) ZA200303668B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO328803B1 (no) 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
CN100351259C (zh) 2002-06-20 2007-11-28 Icvec有限公司 含硫的磷脂衍生物
WO2005073164A1 (en) * 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
AU2005264782B2 (en) * 2004-07-19 2010-12-16 Thia Medica As Composition comprising protein material and non-oxidizable fatty acid entities
WO2009006668A1 (en) * 2007-02-05 2009-01-15 Children, Youth And Women's Health Service Modulators of antigen-dependent t cell proliferation
DE102011050519A1 (de) * 2011-05-20 2012-11-22 Universität Rostock Alkylschwefelalkansäurederivate und ihre pharmazeutisch verträglichen Salze zur Behandlung chronisch entzündlicher Erkrankungen
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
AU2014228387B2 (en) 2013-03-11 2016-09-01 Sciadonics, Inc. Lipid compositions containing bioactive fatty acids
AU2018354090B2 (en) 2017-10-23 2024-10-24 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
WO2019226572A1 (en) 2018-05-23 2019-11-28 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
EP3908374A4 (en) 2019-01-09 2022-12-28 Epitracker, Inc. COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES
EP3934639A4 (en) 2019-03-04 2023-01-11 Epitracker, Inc. FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE DISORDERS, BEHAVIORAL DISORDERS AND CHRONIC PAIN
WO2023080939A1 (en) 2021-11-03 2023-05-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56164120A (en) * 1980-05-22 1981-12-17 Chisso Corp Antitumor agent
FR2631339B1 (fr) * 1988-05-10 1990-11-16 Cird Nouveaux eicosanoides sulfures et leur application en pharmacie et en cosmetique
DE4120917A1 (de) * 1991-06-25 1993-01-07 Basf Ag Ester von fettsaeuren mit aminoalkoholen zur verwendung bei der bekaempfung von krankheiten
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
IL103932A (en) * 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5618955A (en) 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
DE69524639T2 (de) * 1994-10-13 2002-08-08 Peptech Ltd., North Ryde Modifizierte mehrfach ungesättigte fettsäuren
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
RU2089179C1 (ru) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
EP0904072A4 (en) 1996-04-12 2003-07-30 Peptide Technology Pty Ltd METHOD FOR TREATING IMMUNO PATHOLOGIES USING MULTIPLE UNSATURATED FETAL ACIDS
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
AUPQ291499A0 (en) 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds

Also Published As

Publication number Publication date
US20120101161A1 (en) 2012-04-26
AU2002223162B2 (en) 2006-11-30
RU2259823C2 (ru) 2005-09-10
ES2326159T3 (es) 2009-10-02
NZ525889A (en) 2004-10-29
KR20030055322A (ko) 2003-07-02
MXPA03004427A (es) 2004-05-04
ZA200303668B (en) 2004-01-30
CN1633284A (zh) 2005-06-29
US20050165103A1 (en) 2005-07-28
HK1073793A1 (en) 2005-10-21
CN1296039C (zh) 2007-01-24
CA2457925A1 (en) 2002-06-06
NO20006008L (no) 2002-05-29
AU2316202A (en) 2002-06-11
JP2004514693A (ja) 2004-05-20
DE60138834D1 (de) 2009-07-09
EP1351672B1 (en) 2009-05-27
KR100905335B1 (ko) 2009-07-01
CA2457925C (en) 2013-03-26
WO2002043728A1 (en) 2002-06-06
ATE432071T1 (de) 2009-06-15
US8088825B2 (en) 2012-01-03
EP1351672A1 (en) 2003-10-15
NO20006008D0 (no) 2000-11-28
JP4368579B2 (ja) 2009-11-18

Similar Documents

Publication Publication Date Title
AU2316202A (en) Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
CY1110259T1 (el) Ανοσορυθμιστης
EP1809280A4 (en) MITOTIC KINESINE INHIBITORS AND METHOD OF USE THEREOF
AP2001002217A0 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids.
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
EA200100103A1 (ru) Ингибиторы адгезии клеток
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
DE60109938D1 (de) Zusammenstellungen die aktive stilbenoidverbindungen enthalten zur senkung des triglyceridspiegels
DK1265630T3 (da) Anvendelse af insulin til behandling af brusksygdomme
CY1114445T1 (el) Ενωσεις 2,4-πυριμιδινοδιαμινης για χρηση στη θεραπευτικη αγωγη ή προληψη αυτοανοσων ασθενειων
AU4077701A (en) Agent for use in method of treatment
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
IT1288290B1 (it) Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
MA26955A1 (fr) INHIBITEURS DES RECEPTEURS EP4 POUR LE TRAITEMENT DE L'ARTHRITE RHUMATOiDE
NZ337769A (en) Methods and compositions for modulating responsiveness to corticosteroids
BR9811094A (pt) Agente terapêutico para tumores linfáticos
EE200200463A (et) IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks või ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
EA200100732A1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
MX9305621A (es) (s)-(+)-hidroxicloroquina.
BR9914940A (pt) Método para aperfeiçoar a farmacocinética de tipranavir
BR0214810A (pt) Combinação de um inibidor de il-1/18 com um inibidor de tnf para o tratamento de inflamação
FR2834889B1 (fr) Forme pharmaceutique solide orodispersible
SE9603725D0 (sv) New teatment
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
DE60131393D1 (de) Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2282 DE 30/09/2014.